Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Non-Current Assets (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Non-Current Assets readings, the most recent being $720000.0 for Q4 2024.

  • On a quarterly basis, Non-Current Assets fell 9.09% to $720000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $2.9 million, a 19.99% decrease, with the full-year FY2024 number at $720000.0, down 9.09% from a year prior.
  • Non-Current Assets hit $720000.0 in Q4 2024 for Unicycive Therapeutics, down from $833000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.0 million in Q1 2023 to a low of $174000.0 in Q4 2022.
  • Median Non-Current Assets over the past 4 years was $709000.0 (2024), compared with a mean of $601461.5.
  • Biggest five-year swings in Non-Current Assets: tumbled 47.75% in 2022 and later skyrocketed 355.17% in 2023.
  • Unicycive Therapeutics' Non-Current Assets stood at $333000.0 in 2021, then tumbled by 47.75% to $174000.0 in 2022, then skyrocketed by 355.17% to $792000.0 in 2023, then fell by 9.09% to $720000.0 in 2024.
  • The last three reported values for Non-Current Assets were $720000.0 (Q4 2024), $833000.0 (Q3 2024), and $647000.0 (Q2 2024) per Business Quant data.